Sylvester Comprehensive Cancer Center

E-mail a Friend

Israel Wiznitzer, M.D.

General Information

Israel  Wiznitzer, M.D.

Contact

  • Fax: 954-210-1125

Languages

  • English

Certifications

  • American Board of Internal Med-Medical Oncology
  • American Board of Internal Medicine

CV

Specialties

  • Hematology/Oncology - Internal Medicine
  • Internal Medicine

Roles

  • Assistant Professor of Clinical Medicine

Clinical Interests

Benign Hematology
Bone and Soft Tissue Cancer (Sarcoma)
Breast Cancer
Colorectal Cancer
Esophageal and Stomach Cancer
Gynecological Cancer
Head & Neck Cancer
Leukemia, Multiple Myeloma and Related Blood Cancer
Liver (Pimary) Cancer
Lymphoma, CLL/SLL, Leukemia (Hairy Cell)
Melanoma and Skin Cancers
Neuro-Oncology (Primary Brain and Spine tumors)
Pancreatic and Biliary Cancer
Prostate, Kidney, Bladder, Testis and Adrenocortical Cancer
Thoracic Cancer
Thyroid and Related Endocrine Tumors

Awards

Health Grades Honor Roll Physician
Member American Society of Clinical Oncololgy

Education

Honors Program in Medical Education; Medical Internship & Residency
Northwestern University Medical School
Post Doctoral Fellowship - Medical Oncology
Yale University School of Medicine

Publications

  • C Benz, I Wiznitzer, CL Benz: Steroind binding and cytotoxicity in cultured human pancreatic carcinomas. In: Hormones and Cancer 2. Raven Press, NY 223-228, 1984
  • C Benz, I Wiznitzer, SH Lee: Flow cytometric analysis of fluorescent estrogen bindingin cancer cell suspensions. In: Morphologic Localization of Positive Steroid Receptors, Vol 1: Experimental Systems. CRC Press, Boca Raton, FL 95-110, 1985.
  • C Benz, I Wiznitzer, SH Lee: Flow cytometric analysis of fluorescein-conjugated estradiol binding in breast cancer suspensions. Cytometry 6; 260-268, 1985
  • FA Holmes, JA O'Shaugnessy, S Vukeja, J Shogan, J Glaspy, M Moore, L Meza, I Wiznitzer, TA Neumann, LR Hil, BC Liang. Blinded, Randomized Multicenter Study to Evaluate Single Administration of Pegfilgrastim Once per Cycle vs Daily Filgrastim as an Adjunct to Chemotherapy in Patients with High Risk Stage II or Stage III/IV Breast Cancer. Journal of Clinical Oncology 20: 727-731, 2002.
  • JS Rader, D Clarke-Pearson, M Moore, L Carson, R Holloway, MS Kao, I Wiznitzer, EC Douglass. A Phase II Study to Determine the Efficacy and Tolerability of Intravenous ZD9331 in Heavily Pre-treated Patients with Ovarian Cancer. Gynecologic Oncology 2003
  • International Adjuvant Lung Cancer Collaborative Group (I Wiznitzer as a contributing member). Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer. NEJM 350: 351-360. January 22, 2004
  • JB Bussel MD, DJ Kuter MD, JN George MD, R McMillan MD, LM Aledort MD, GT Conklin MD, AE Lichtin MD, RM Lyons MD, J Nieva MD, JS Wasser MD, I Wiznitzer MD, R Kelly BS, CF Chen PhD, JL Nichol MS. AMG 531, a Thrombopoiesis-Stimulating Protein for Chronic ITP. NEJM 355: 1672-1681. October 19, 2006

E-mail a Friend